System-Specific Biopharmaceuticals

JCR Pharmaceuticals Co., Ltd.

4552

JCR Pharmaceuticals presented promising preclinical data on its JUST-AAV gene therapy platform at the ASGCT 29th Annual Meeting. The technology aims to enhance delivery to the central nervous system while reducing liver tropism. Results showed improved CNS uptake and therapeutic efficacy in models of GM1 gangliosidosis and neuronal ceroid lipofuscinosis. The findings support the potential for new treatment options for challenging CNS diseases, with plans for first-in-human clinical trials.

MorningStar

AstraZeneca

AstraZeneca PLC

JCR Pharmaceuticals Presents Preclinical Gene Therapy Data that Demonstrate Promising Central Nervous System Uptake at the American Society of Gene and Cell Therapy (ASGCT) 29th Annual Meeting

JCR Pharmaceuticals (TSE:4552) reported FY 2026 results with Q4 revenue of ¥9,966 million and basic EPS of ¥3.56, marking a shift from previous losses. Despite a one-off gain of ¥2,500 million impacting profits, analysts expect 19.2% annual earnings growth. The stock trades at a high 30x P/E, with modest revenue growth forecasted at 0.03%. Quarterly earnings have been uneven, raising concerns about sustainability. Investors are advised to consider long-term trends and the company's financial stability.

Simplywall

JCR Pharmaceuticals (TSE:4552) One Off Gain Driven Profit Challenges Bullish Earnings Narratives

3962

4310

3042

Japan's IPO market is experiencing its longest streak of first-day flops since 2020, with several companies, including J-Pharma and Basic, seeing significant drops in their stock prices. This trend reflects shaken investor sentiment due to the ongoing war in Iran, leading to a technical correction in Japanese stocks. The number of IPOs has also decreased, with only seven deals priced this year, the lowest since 2011. Portfolio managers are becoming more cautious, opting for secondary market investments instead of new listings.

Businesstimes News

Change, Inc. (Japan)

Dream Incubator Inc.

SecuAvail, Inc.

Pro Ultrshrt Yen

Japan posts longest streak of first-day IPO flops since 2020

JCR Pharmaceuticals presented research at WORLDSymposium™ 2026, showcasing data on investigational treatments for lysosomal storage disorders (LSDs). The presentations highlighted the potential benefits of therapies using J-Brain Cargo®, a proprietary technology for delivering medicines across the blood-brain barrier. Key findings included pre-clinical data on JR-471 for fucosidosis and long-term efficacy of JR-141 for Hunter syndrome. The data suggest promising outcomes in treating these rare diseases, which often lack effective therapies.

JCR Pharmaceuticals’ Research Presentations at WORLDSymposium™ 2026 Showcase Data from Its Investigational Treatments for Lysosomal Storage Disorders

Jefferies analyst maintained a Hold rating on JCR Pharmaceuticals Co., Ltd. today and set a price target of Yen750.00.Claim 50% Off TipRanks PremiumUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential The word on The Street in general, suggests a Hold analyst consensus rating for JCR Pharmaceuticals Co., Ltd. with a Yen750.00 average price target.

Tip Ranks

Jefferies Sticks to Their Hold Rating for JCR Pharmaceuticals Co., Ltd. (4552)

JCR Pharmaceuticals Co., Ltd.(4552.JP)

JCR Pharmaceuticals Presents Preclinical Gene Therapy Data that Demonstrate Promising Central Nervous System Uptake at the American Society of Gene and Cell Therapy (ASGCT) 29th Annual Meeting

JCR Pharmaceuticals (TSE:4552) One Off Gain Driven Profit Challenges Bullish Earnings Narratives

Japan posts longest streak of first-day IPO flops since 2020

JCR Pharmaceuticals’ Research Presentations at WORLDSymposium™ 2026 Showcase Data from Its Investigational Treatments for Lysosomal Storage Disorders

Jefferies Sticks to Their Hold Rating for JCR Pharmaceuticals Co., Ltd. (4552)